Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) FCF Margin (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed FCF Margin for 13 consecutive years, with 1.71% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin fell 2752.0% to 1.71% in Q4 2025 year-over-year; TTM through Dec 2025 was 10.21%, a 179.0% decrease, with the full-year FY2025 number at 10.21%, down 179.0% from a year prior.
  • FCF Margin was 1.71% for Q4 2025 at Niagen Bioscience, down from 10.89% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 29.23% in Q4 2024 to a low of 46.1% in Q2 2021.
  • A 5-year average of 5.91% and a median of 1.43% in 2024 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: plummeted -3653bps in 2021, then soared 5383bps in 2023.
  • Niagen Bioscience's FCF Margin stood at 27.85% in 2021, then soared by 91bps to 2.38% in 2022, then skyrocketed by 224bps to 2.96% in 2023, then surged by 887bps to 29.23% in 2024, then crashed by -94bps to 1.71% in 2025.
  • Per Business Quant, the three most recent readings for NAGE's FCF Margin are 1.71% (Q4 2025), 10.89% (Q3 2025), and 3.42% (Q2 2025).